Patterns of medical practice in cystic fibrosis: Part II. Use of therapies
- 1 October 1999
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 28 (4) , 248-254
Abstract
This report describes the prescribing pattern of therapeutic interventions in the management of patients with cystic fibrosis (CF), as observed in the Epidemiologic Study of Cystic Fibrosis (ESCF). Use of 20 therapies by 12,622 patients was recorded from each health care encounter (53,024 outpatient visits and 8,561 hospitalizations) during a 1-year period (1995), and analyzed by gender, age, severity of lung disease, and presence of any Pseudomonas species in the respiratory tract. The percentage of patients using the following pulmonary therapies was observed (in descending order): airway clearance techniques (88.2%); inhaled bronchodilators (82.2%); oral antibiotics (excluding quinolones) (68.2%); dornase alfa (52.9%); intravenous antibiotics (34.4%); oral quinolones (34.4%); inhaled antibiotics (34.3%); mast cell stabilizers (29.5%); inhaled corticosteroids (25.9%); oral corticosteroids (17.1%); oral bronchodilators (16.2%); oxygen (8.1%); inhaled mucolytic agent acetyl cysteine (6.5%); and diuretics (1.4%). The percentage of patients using nutritional therapies was: pancreatic enzymes (96%); oral nutritional supplements (31.1%); enteral nutrition (7.3%); and parenteral nutrition (0.7%). The percentage of patients using other therapies was: nonsteroidal anti-inflammatory drugs (7.9%); and insulin or oral hypoglycemic agents (6.1%). The general trend was for therapies to be used more by older patients, those with lower pulmonary function, and by those with Pseudomonas in their respiratory tract. Exceptions to this trend occurred for airway clearance, oral antibiotics, mast cell stabilizers, and pancreatic enzymes. Four therapies (oral nutritional supplements, parenteral nutrition, diuretics, and pancreatic enzymes) were used more by males than females. However, there was no gender difference for this group of therapies on pulmonary or nutritional status. Pediatr Pulmonol. 1999; 28:248–254.Keywords
This publication has 16 references indexed in Scilit:
- Patterns of medical practice in cystic fibrosis: Part I. Evaluation and monitoring of health status of patientsPediatric Pulmonology, 1999
- Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: A bronchoscopic studyThe Journal of Pediatrics, 1998
- Increased DNA Levels in Bronchoalveolar Lavage Fluid Obtained From Infants With Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 1996
- Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 1996
- Effects of 12-Week Administration of Dornase Alfa in Patients with Advanced Cystic Fibrosis Lung DiseaseChest, 1996
- Management of Pulmonary Disease in Patients with Cystic FibrosisNew England Journal of Medicine, 1996
- A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosisThe Journal of Pediatrics, 1995
- Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic FibrosisNew England Journal of Medicine, 1994
- Cystic fibrosis foundation consensus conference report on pulmonary complications of cystic fibrosisPediatric Pulmonology, 1993
- Nutritional assessment and management in cystic fibrosis: a consensus reportThe American Journal of Clinical Nutrition, 1992